Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Drug Importation

Mayor Pannullo Opinion: Drug Importation Threatens Backbone of New Jersey’s Economy

The Honorable Joseph Pannullo

East Hanover, NJ, March 31, 2017In an op-ed published in The Record on March 22, East Hanover Mayor Joseph Pannullo wrote:

Millions of Americans’ lives are riding on the success of a few New Jersey companies.

Garden State pharmaceutical firms account for nearly 30 percent of all diabetes and heart disease treatments in development.  These two diseases alone kill hundreds of thousands of Americans each year.  And they’re driving U.S. healthcare costs through the roof.

Those treatments may never reach patients if some in Washington push forward with a plan to allow patients to import foreign prescription drugs.   Continue reading

Former FDA Commissioners Denounce Drug Importation, Citing Dangers to Consumers

Washington, DC, March 21, 2017 — Laurie McGinley reports in The Washington Post that the four most recent Food and Drug Administration (FDA) commissioners are warning Congress that legalizing the importation of drugs from other countries — an idea that has drawn support from both Bernie Sanders and President Trump — is a risky approach that would endanger consumers by exposing them to fake, substandard and contaminated drugs.

The open letter to members of Congress, which was posted Friday by the Margolis Center for Health Policy at Duke University, was signed by two former FDA heads who served during the Obama administration — Robert Califf and Margaret Hamburg — and two who served under former president George W. Bush — Andrew von Eschenbach and Mark McClellan. Continue reading

Trump Health Care Plan Would Allow Drug Importation; Industry Opposes

Donald Trump 1Boston, MA, March 3, 2016 ― David Nather reports on STAT that Donald Trump released a health care plan Wednesday that includes common Republican ideas for replacing Obamacare but departs from conventional GOP policies in one major way: it would allow the reimportation of cheaper drugs from overseas.

Nather reports that this is the second time that front-runner Trump has embraced an idea to bring down drug costs that’s associated more with Democrats like Hillary Clinton and Bernie Sanders than with the party he’s trying to lead.

Trump has previously said that Medicare should be allowed to negotiate drug prices, which is also a centerpiece of the Clinton and Sanders plans to bring down drug prices.  That idea doesn’t appear anywhere in the health care plan he released Wednesday. Continue reading